GLP1R and type 2 diabetes mellitus: The metabolic importance of physiological oxyntomodulin release is difficult to disentangle from the effects of GLP‐1 and glucagon, but drugs that mimic oxyntomodulin action by acting as dual GLP1R/GCGR agonists are proving highly effective in clinical trials for type 2 diabetes, metabolism dysfunction‐associated steatotic liver disease and obesity (Winther & Holst, 2024).